NK - NantKwest surges on FDA clearance to expand Phase 1 trial for COVID-19 vaccine

NantKwest, Inc. (NK) is up ~12.9% in the premarket after the company and its privately-held partner, ImmunityBio announced the FDA approval to expand the Phase I study of its T cell-based COVID-19 vaccine candidate.The cohort C expansion to the Phase 1 trial evaluating the subcutaneous version of the experimental bivalent hAd5 T-cell COVID-19 vaccine will study the effect of the addition of sublingual boosts.And a second Phase I study will also commence to evaluate the addition of an oral boost to the subcutaneous prime administration.Based on the amended trial involving additional 105 participants in the U.S., the companies will determine the optimal combination of the route of administration and the dose suitable for the Phase 2 / 3 design.The first two cohorts of the Phase Ib, open-label, dose-ranging study of the vaccine received two different dose levels (.5 and 1ml) in two subcutaneous injections 21 days apart.The additional group of 40 subjects will

For further details see:

NantKwest surges on FDA clearance to expand Phase 1 trial for COVID-19 vaccine